Suppr超能文献

下丘脑 - 垂体 - 甲状腺轴:促甲状腺激素释放激素(TRH)调节作用的研究(作者译)

[The hypothalamic-Pituitary thyroid axis: studies on the regulatory role of thyrotropin releasing hormone (TRH) (author's transl)].

作者信息

Hirooka Y

出版信息

Nihon Naibunpi Gakkai Zasshi. 1976 Sep 20;52(9):908-25. doi: 10.1507/endocrine1927.52.9_908.

Abstract

These studies were undertaken to clarify the physiological role of thyrotropin releasing hormone (TRH) in regulation of the hypothalamic pituitary thyroid axis. Synthetic TRH was administered both acutely as a single intravenous dose of 500 micrograms (TRH IV) and chronically (TRH p.o.), in the form of repetitive oral doses (10 mg b.i.d. for 4 days) to 21 normal, 26 hypothyroid, and 14 hyperthyroid subjects. Serial determinations were made of the serum levels of thyrotropin (TSH), triiodothyronine (T3) and thyroxine (T4) after TRH IV nd TRH p.o. and changes in thyroidal untake of redioiodine thyroxine were assessed after TRH p.o. In normal subjects, serum TSH and T3 rose in response to TRH IV but there was no significant change in the serum T4 levels. The peak levels of serum TSH (TSH PL) ranged from 7.0 to 30.0 microunits per ml and serum T3 levels (T3 PL) from 126.2 to 197.4 ng/dl. After the first TRH p.o. dose, serum TSH levels rose (TSH PL: 7.0 approximately 34.0 microunits per ml) but the TSH increment decreased in response to subsequent doses of TRH . Nevertheless, both the mean serum T3 and T4 levels increased progressively in response to TRH p.o. reaching their peak levels on the 4th day (Mean T3 PL: 185.1 +/- 4.0 ng/dl with a range of 152.8 to 216.8; Mean T4 PL:11.7 +/- 0.8 micrograms/dl with a range of 8.4 to 13.4). The mean 24-hour131I uptake also increased by 19.9 +/- 1.2% D over baseline with a range 9.1 to 30.7. After intramuscular TSH, the mean increment in a 24-hour 131I uptake was 13.2 +/- 1.0% D with a range of 5.6 to 20.8%. In all 26 patients with hypothyroidism, serum T3 and T4 failed to increase in response to TRH IV. Based on the TSH PL after TRH IV and the criteria of Pittman, the patients could be provisionally divided into primary hypothyroidism (13 patients whose TSH PL ranged from 52.5 to 500 microunits per ml), secondary or pituitary hypothyroidism (8 patients whose TSH PL varied from undetectable to 4.1 microuints/ml) and tertiary or hypothalamic hypothyroidism (5 patients whose TSH PL was from 8.8 to 30.4 microunits/ml)...

摘要

开展这些研究是为了阐明促甲状腺激素释放激素(TRH)在下丘脑 - 垂体 - 甲状腺轴调节中的生理作用。将合成TRH分别以单次静脉注射500微克(TRH静脉注射)的急性方式以及慢性方式(TRH口服)给予21名正常受试者、26名甲状腺功能减退受试者和14名甲状腺功能亢进受试者,慢性方式即重复口服给药(每日两次,每次10毫克,共4天)。在TRH静脉注射和TRH口服后,连续测定促甲状腺激素(TSH)、三碘甲状腺原氨酸(T3)和甲状腺素(T4)的血清水平,并在TRH口服后评估甲状腺对放射性碘甲状腺素摄取的变化。在正常受试者中,血清TSH和T3对TRH静脉注射有反应而升高,但血清T4水平无显著变化。血清TSH峰值水平(TSH PL)为每毫升7.0至30.0微单位,血清T3水平(T3 PL)为126.2至197.4纳克/分升。首次TRH口服给药后,血清TSH水平升高(TSH PL:约每毫升7.0至34.0微单位),但后续TRH给药后TSH增量减少。然而,血清T3和T4的平均水平均因TRH口服而逐渐升高,在第4天达到峰值水平(平均T3 PL:185.1±4.0纳克/分升,范围为152.8至216.8;平均T4 PL:11.7±0.8微克/分升,范围为8.4至13.4)。24小时平均131I摄取量也比基线增加了19.9±1.2%,范围为9.1至30.7。肌肉注射TSH后,24小时131I摄取量的平均增量为13.2±1.0%,范围为5.6至20.8%。在所有26例甲状腺功能减退患者中,血清T3和T4对TRH静脉注射无反应而未升高。根据TRH静脉注射后的TSH PL以及皮特曼标准,患者可初步分为原发性甲状腺功能减退(13例,TSH PL范围为每毫升52.5至500微单位)、继发性或垂体性甲状腺功能减退(8例,TSH PL从不可测至4.1微单位/毫升不等)和三级或下丘脑性甲状腺功能减退(5例,TSH PL为8.8至30.4微单位/毫升)……

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验